Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Cystectomy for Bladder Cancer
share announcement

Cystectomy for Bladder Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 2818

Special Issue Editor

Dr. Tobias Klatte

E-Mail Website
Guest Editor
Department of Urology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany
Interests: bladder cancer; kidney cancer

Special Issue Information

Cystectomy remains the standard of care for muscle-invasive bladder cancer. During recent years, there has been a refinement regarding perioperative systemic therapy, surgical techniques, pathology, postoperative protocols, and prognostic factors. This Special Issue will present a selection of original articles and reviews which focus on the recent advances and current challenges in the field of cystectomy for bladder cancer.

Dear Colleagues,

We would love for you contribute to a Special Issue of Cancers, entitled “Cystectomy for bladder cancer”. During recent years, there has been a refinement regarding several aspects in preoperative, intraoperative, and postoperative pathways and management. This Special Issue of Cancers aims to present a selection of original articles and reviews which describe the recent advances and current challenges in the field. Specifically, we aim to provide a comprehensive understanding of all aspects of cystectomy to point out modern approaches that are state-of-the-art. Research areas may include (but are not limited to) surgical techniques (e.g., open versus robotic cystectomy, urinary diversion), the impact of enhanced recovery protocols, perioperative systemic therapy, pathological and genetic prognostic markers, as well as volume outcome relationships. Metabolic, immunological, and other specific features of muscle-invasive bladder cancer are also of interest. Thus, we are pleased to invite manuscripts that aid the translation of data into routine clinical practice for more specific and individual therapeutic options for this disease. We look forward to receiving your contributions.

Dr. Tobias Klatte
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bladder cancer
  • cystectomy
  • chemotherapy
  • immunotherapy
  • complications
  • lymph node dissection
  • robotics
  • prognosis
  • enhanced recovery

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 483 KiB  
Article
One-Year Follow-Up after Multimodal Prehabilitation Interventions in Radical Cystectomy
by Bente Thoft Jensen and Jørgen Bjerggaard Jensen
Cancers 2023, 15(24), 5785; https://doi.org/10.3390/cancers15245785 - 10 Dec 2023
Viewed by 747
Abstract
Multimodal prehabilitation is the process of enhancing physiological, nutritional, and psychological resilience to increase patients’ functional capacity before major cancer surgery and aims to empower the patient to withstand the pending stress of major surgery and ultimately to improve long-term outcomes. The effect [...] Read more.
Multimodal prehabilitation is the process of enhancing physiological, nutritional, and psychological resilience to increase patients’ functional capacity before major cancer surgery and aims to empower the patient to withstand the pending stress of major surgery and ultimately to improve long-term outcomes. The effect of physical prehabilitation to counteract the physical decline in surgical cancer patients has been documented; however, long-term results have not yet been published. This follow-up study aims to evaluate 1-year results on the efficacy of physical prehabilitation after bladder cancer surgery. The efficacy of prehabilitation was measured over the course of 1 year in 107 patients randomized to (1) pre- and rehabilitation or (2) standard care divided by n = 50 in the intervention (I) and n = 57 in the standard group (S). Physical function was measured by muscle leg power, and nutritional status was expressed with handgrip strength. Prehabilitation in major bladder cancer surgery can significantly improve physical function with 19.8 Watt/kg (p = 0.04), lean body mass (p = 0.047) and body cell mass (p = 0.03), and regained nutritional status one year after surgery. The results demonstrate that the restoration of physical function is vital to a full recovery. Full article
(This article belongs to the Special Issue Cystectomy for Bladder Cancer)
►▼ Show Figures

Figure 1

14 pages, 1726 KiB  
Article
Influence of Neoadjuvant Chemotherapy on Survival Outcomes of Radical Cystectomy in Pathologically Proven Positive and Negative Lymph Nodes
by Krystian Kaczmarek, Bartosz Małkiewicz, Karolina Skonieczna-Żydecka and Artur Lemiński
Cancers 2023, 15(19), 4901; https://doi.org/10.3390/cancers15194901 - 09 Oct 2023
Viewed by 968
Abstract
Patients receiving neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) typically show better survival outcomes than those undergoing immediate surgery for muscle-invasive bladder cancer. However, most studies have not considered the lymph node (LN) status when evaluating NAC’s survival benefits. This study sought [...] Read more.
Patients receiving neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) typically show better survival outcomes than those undergoing immediate surgery for muscle-invasive bladder cancer. However, most studies have not considered the lymph node (LN) status when evaluating NAC’s survival benefits. This study sought to delineate the impact of NAC on patients based on their pathologically determined LN status at the time of RC. We examined data from 1395 patients treated at two departments between 1991 and 2022. Of them, 481 had positive LNs. A comparison of overall survival (OS) outcomes revealed that patients without LN involvement ((y)pN0) benefited from NAC with a hazard ratio (HR) of 0.692 (95% confidence interval [CI] 0.524–0.915). In contrast, patients with (y)pN+ showed no improvement with NAC (HR 0.927, 95%CI 0.713–1.205). Notably, patients treated with NAC for stage <ypT2ypN+ tumours experienced reduced OS compared to their counterparts who did not receive NAC. The HR was 3.111 (95%CI 1.249–7.746). Given that persistent nodal disease after NAC correlates with a worse prognosis, additional post-operative treatments should be considered. Full article
(This article belongs to the Special Issue Cystectomy for Bladder Cancer)
►▼ Show Figures

Figure 1

13 pages, 389 KiB  
Article
Retrospective Evaluation of a Single Surgeon’s Learning Curve of Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion via Ileal Conduit
by Christof Achermann, Andreas Sauer, Marco Cattaneo, Jochen Walz, Stephen F. Wyler, Maciej Kwiatkowski and Lukas W. Prause
Cancers 2023, 15(15), 3799; https://doi.org/10.3390/cancers15153799 - 26 Jul 2023
Viewed by 659
Abstract
Robot-assisted radical cystectomy with intracorporeal urinary diversion (iRARC) is increasingly being performed instead of open surgery. A criticism of this technique is the long learning curve, but limited data are available on this topic. At our center, the transition from open radical cystectomy [...] Read more.
Robot-assisted radical cystectomy with intracorporeal urinary diversion (iRARC) is increasingly being performed instead of open surgery. A criticism of this technique is the long learning curve, but limited data are available on this topic. At our center, the transition from open radical cystectomy (ORC) to iRARC began in May 2017. A retrospective analysis was conducted on the initial 53 cases of robot-assisted cystectomy with intracorporeal urinary diversion via ileal conduit, which were performed by one single surgeon. The patients were divided into four consecutive groups according to the surgeon’s increasing experience, and perioperative parameters were analyzed as a surrogate for the learning curve. Over the course of the learning curve, a decline in median operation time from 415 to 361 min (p = 0.02), blood loss from 400 to 200 mL (p = 0.01), and minor complications from 71% to 15% (p = 0.02) was observed. No significant difference in overall and major complications, length of hospital stay, and total lymph node yield was shown. During the initial period of the learning curve, only the less complex cases were operated on using robotic surgery, while the more challenging ones were handled through open surgery. After experience with 28 cases, no more cystectomies were performed through open surgery. This led to an increase in operation time and length of hospital stay, as well as a higher incidence of both minor and overall complications among cases 28–40. After 40 cases, a significant decrease in these parameters was observed again. Our analysis demonstrated that operation time, blood loss, and minor complications decrease with increasing surgical experience in iRARC, while suggesting that technically challenging cases should be operated on after experience with 40 robotic cystectomies. Full article
(This article belongs to the Special Issue Cystectomy for Bladder Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop